Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) is set to post its quarterly earnings results before the market opens on Wednesday, August 7th. Analysts expect Intra-Cellular Therapies to post earnings of ($0.19) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.
Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) last issued its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.15. The company had revenue of $144.90 million for the quarter, compared to analyst estimates of $141.41 million. Intra-Cellular Therapies had a negative net margin of 21.57% and a negative return on equity of 18.49%. The business’s revenue for the quarter was up 52.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.46) earnings per share. On average, analysts expect Intra-Cellular Therapies to post $-1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Intra-Cellular Therapies Trading Down 0.1 %
Shares of NASDAQ:ITCI opened at $78.10 on Wednesday. The firm’s 50-day moving average is $72.01 and its two-hundred day moving average is $70.06. Intra-Cellular Therapies has a 1 year low of $45.50 and a 1 year high of $84.89.
Analysts Set New Price Targets
Check Out Our Latest Stock Analysis on Intra-Cellular Therapies
Insider Buying and Selling at Intra-Cellular Therapies
In other Intra-Cellular Therapies news, Director Nostrand Robert L. Van sold 20,000 shares of the stock in a transaction that occurred on Tuesday, June 18th. The shares were sold at an average price of $75.91, for a total value of $1,518,200.00. Following the transaction, the director now directly owns 9,690 shares in the company, valued at $735,567.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Intra-Cellular Therapies news, Director Rory B. Riggs sold 4,462 shares of the stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $75.57, for a total value of $337,193.34. Following the transaction, the director now directly owns 116,600 shares in the company, valued at $8,811,462. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Nostrand Robert L. Van sold 20,000 shares of the stock in a transaction that occurred on Tuesday, June 18th. The shares were sold at an average price of $75.91, for a total transaction of $1,518,200.00. Following the completion of the transaction, the director now owns 9,690 shares in the company, valued at $735,567.90. The disclosure for this sale can be found here. 3.40% of the stock is currently owned by insiders.
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
Further Reading
- Five stocks we like better than Intra-Cellular Therapies
- 3 Warren Buffett Stocks to Buy Now
- Invest Like Congress: 2 ETFs to Add to Your Watchlist
- Using the MarketBeat Dividend Tax Calculator
- AI Boom or Bubble? Strategies for Success in a Volatile Sector
- Investing in the High PE Growth Stocks
- Oilfield Infrastructure Stock Soars Over 50% on Bold Acquisition
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.